Insulin Glargine and Cancer Risk in Patients with Diabetes: A Meta-Analysis

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Tang, Xulei ^a   Yang, Lin ^a   He, Zhiyu ^a   Liu, Jingfang ^a  

^a LANZHOU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN DERIVATIVE; INSULIN GLARGINE; ISOPHANE INSULIN;

ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER INCIDENCE; CANCER PATIENT; CANCER RISK; COHORT ANALYSIS; COLORECTAL CANCER; DIABETES MELLITUS; DIGESTIVE SYSTEM CANCER; HEPATOBILIARY SYSTEM CANCER; HUMAN; LOW RISK POPULATION; META ANALYSIS; NEOPLASM; OBSERVATIONAL STUDY; PANCREAS CANCER; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT CANCER; SYSTEMATIC REVIEW;

DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN, LONG-ACTING; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 84871301614     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051814     Document Type: Article

References (45)

1. Whiting DR, Guariguata L, Weil C, Shaw J, (2011) IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 94: 311-321.
2. American Diabetes Association (2012) Diagnosis and classification of diabetes mellitus. Diabetes Care 35 Suppl 1: S64-71.
3. Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, et al. (2000) Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 23: 644-649.
4. Rosenstock J, Dailey G, Massi-Benedetti M, Fritsche A, Lin Z, et al. (2005) Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care 28: 950-955.
5. Currie CJ, Poole CD, Gale EA, (2009) The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52: 1766-1777.
6. Jonasson JM, Ljung R, Talback M, Haglund B, Gudbjornsdottir S, et al. (2009) Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia 52: 1745-1754.
7. Colhoun HM, (2009) Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 52: 1755-1765.
8. Hemkens LG, Grouven U, Bender R, Gunster C, Gutschmidt S, et al. (2009) Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 52: 1732-1744.
9. Smith U, Gale EA, (2009) Does diabetes therapy influence the risk of cancer? Diabetologia 52: 1699-1708.
10. Dawson LK, Hamilton LA, (2010) Risk of cancer in patients receiving insulin glargine. Am J Health Syst Pharm 67: 2025-2031.
11. Weinstein D, Simon M, Yehezkel E, Laron Z, Werner H, (2009) Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activities in cultured cancer cells. Diabetes Metab Res Rev 25: 41-49.
12. Shukla A, Grisouard J, Ehemann V, Hermani A, Enzmann H, et al. (2009) Analysis of signaling pathways related to cell proliferation stimulated by insulin analogs in human mammary epithelial cell lines. Endocr Relat Cancer 16: 429-441.
13. Eckardt K, May C, Koenen M, Eckel J, (2007) IGF-1 receptor signalling determines the mitogenic potency of insulin analogues in human smooth muscle cells and fibroblasts. Diabetologia 50: 2534-2543.
14. Staiger K, Staiger H, Schweitzer MA, Metzinger E, Balletshofer B, et al. (2005) Insulin and its analogue glargine do not affect viability and proliferation of human coronary artery endothelial and smooth muscle cells. Diabetologia 48: 1898-1905.
15. Wada T, Azegami M, Sugiyama M, Tsuneki H, Sasaoka T, (2008) Characteristics of signalling properties mediated by long-acting insulin analogue glargine and detemir in target cells of insulin. Diabetes Res Clin Pract 81: 269-277.
16. Moher D, Liberati A, Tetzlaff J, Altman DG, (2010) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 8: 336-341.
17. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, et al. (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283: 2008-2012.
18. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, et al. (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336: 924-926.
19. Schünemann H, Brożek J, Oxman A, editors (2011) GRADE handbook for grading quality of evidence and strength of recommendation. Version 3.6. Hamilton, Ontario, Canada: McMaster University, GRADE Working Group. Available: http://ims.cochrane.org/revman/gradepro. Accessed 2012 17 Jun.
20. Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, et al. (2011) GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 64: 401-406.
21. DerSimonian R, Laird N, (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177-188.
22. Higgins JP, Thompson SG, (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21: 1539-1558.
23. Ruiter R, Visser LE, van Herk-Sukel MP, Coebergh JW, Haak HR, et al. (2012) Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study. Diabetologia 55: 51-62.
24. Blin P, Lassalle R, Dureau-Pournin C, Ambrosino B, Bernard MA, et al. (2012) Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database. Diabetologia.
25. van Staa TP, Patel D, Gallagher AM, de Bruin ML, (2011) Glucose-lowering agents and the patterns of risk for cancer: a study with the General Practice Research Database and secondary care data. Diabetologia.
26. Suissa S, Azoulay L, Dell'Aniello S, Evans M, Vora J, et al. (2011) Long-term effects of insulin glargine on the risk of breast cancer. Diabetologia 54: 2254-2262.
27. Morden NE, Liu SK, Smith J, Mackenzie TA, Skinner J, et al. (2011) Further exploration of the relationship between insulin glargine and incident cancer: a retrospective cohort study of older Medicare patients. Diabetes Care 34: 1965-1971.
28. Ljung R, Talback M, Haglund B, Jonasson JM, Gudbjornsdottir S, et al. (2011) Insulin glargine use and short-term incidence of malignancies- a three-year population-based observation. Acta Oncol 50: 685-693.
29. Chang CH, Toh S, Lin JW, Chen ST, Kuo CW, et al. (2011) Cancer risk associated with insulin glargine among adult type 2 diabetes patients-a nationwide cohort study. PLoS One 6: e21368.
30. Mannucci E, Monami M, Balzi D, Cresci B, Pala L, et al. (2010) Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care 33: 1997-2003.
31. Rosenstock J, Fonseca V, McGill JB, Riddle M, Halle JP, et al. (2009) Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study. Diabetologia 52: 1971-1973.
32. Home PD, Lagarenne P, (2009) Combined randomised controlled trial experience of malignancies in studies using insulin glargine. Diabetologia 52: 2499-2506.
33. Gerstein HC, Bosch J, Dagenais GR, Diaz R, Jung H, et al. (2012) Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 367: 319-328.
34. Stammberger I, Bube A, Durchfeld-Meyer B, Donaubauer H, Troschau G, (2002) Evaluation of the carcinogenic potential of insulin glargine (LANTUS) in rats and mice. Int J Toxicol 21: 171-179.
35. Stammberger I, Essermeant L, (2012) Insulin Glargine: A Reevaluation of Rodent Carcinogenicity Findings. Int J Toxicol.
36. Muller K, Weidinger C, Fuhrer D, (2010) Insulin glargine and insulin have identical effects on proliferation and phosphatidylinositol 3-kinase/AKT signalling in rat thyrocytes and human follicular thyroid cancer cells. Diabetologia 53: 1001-1003.
37. Teng JA, Hou RL, Li DL, Yang RP, Qin J, (2011) Glargine promotes proliferation of breast adenocarcinoma cell line MCF-7 via AKT activation. Horm Metab Res 43: 519-523.
38. Staiger K, Hennige AM, Staiger H, Haring HU, Kellerer M, (2007) Comparison of the mitogenic potency of regular human insulin and its analogue glargine in normal and transformed human breast epithelial cells. Horm Metab Res 39: 65-67.
39. Liefvendahl E, Arnqvist HJ, (2008) Mitogenic effect of the insulin analogue glargine in malignant cells in comparison with insulin and IGF-I. Hormone and Metabolic Research 40: 369-374.
40. Erbel S, Reers C, Eckstein VW, Kleeff J, Buchler MW, et al. (2008) Proliferation of colo-357 pancreatic carcinoma cells and survival of patients with pancreatic carcinoma are not altered by insulin glargine. Diabetes Care 31: 1105-1111.
41. Nagel JM, Staffa J, Renner-Muller I, Horst D, Vogeser M, et al. (2010) Insulin glargine and NPH insulin increase to a similar degree epithelial cell proliferation and aberrant crypt foci formation in colons of diabetic mice. Horm Cancer 1: 320-330.
42. Boyle P, Koechlin A, Boffetta P, Boniol M, Bolli GB, (2011) Meta-analysis of insulin glargine and cancer risk: No evidence of increased risk of cancer. Diabetes 60: A356.
43. Du X, Zhang R, Xue Y, Li D, Cai J, et al. (2012) Insulin glargine and risk of cancer: a meta-analysis. Int J Biol Markers 27: e241-246.
44. Dejgaard A, Lynggaard H, Rastam J, Thomsen MK, (2009) No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis. Diabetologia 52: 2507-2512.
45. Bodmer M, Meier C, Krahenbuhl S, Jick SS, Meier CR, (2010) Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 33: 1304-1308.